You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address